Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

Arifoğlu, Hasan Basri; Duru, Necati; Altunel, Orhan; Başkan, Burhan; Alabay, Bedirhan; Ataş, Mustafa

doi:10.5935/0004-2749.20160069

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies showed that SFCT of RVO eyes was significantly thicker than that of unaffected fellow eyes [12] [13]. Besides, SFCT change after anti-VEGF therapy was also contradictory [14, 15]. Most of the studies reported that the SFCT was decreased significantly after anti-VEGF treatment [12, 16], while a few studies reported that SFCT didn’t decrease after anti-VEGF treatment [9].…”

Section: Introductionmentioning

confidence: 99%

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

BMC Ophthalmol

View full text Add to dashboard Cite

Background To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion(RVO), and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO). Methods In the retrospective study, we had collected 36-six treatment-naïve patients with unilateral ME secondary to RVO (including 19 CRVO and 17 BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after 2 weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes. Results The mean SFCT at the onset was 326.03 ± 30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes ( p < 0.01, paired t test), and reduced to 294.15 ± 30.83 μm rapidly after 2 weeks of IVR injection ( p < 0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes. Conclusions The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.

show abstract

Section: Introductionmentioning

confidence: 99%

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…However, other studies showed that SFCT of RVO eyes was significantly thicker than that of unaffected fellow eyes [12] [13] . Besides, SFCT change after anti-VEGF therapy was also contradictory [14,15] . Most of the studies reported that the SFCT was decreased significantly after anti-VEGF treatment [12,16] , while a few studies reported that SFCT didn't decrease after anti-VEGF treatment [9] .…”

Section: Introductionmentioning

confidence: 99%

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Tang

Zhong

et al. 2019

Preprint

View full text Add to dashboard Cite

Backgroud: To evaluate the subfoveal choroidal thickness (SFCT) in eyes with macular edema (ME) secondary to retinal vein occlusion（RVO），and to investigate the short term response after a single intravitreal ranibizumab (IVR) injection. What is more, to compare SFCT and SFCT change between central RVO (CRVO) and branch RVO (BRVO). Methods: In the retrospective study, we had collected thirty-six treatment-naïve patients with unilateral ME secondary to RVO (including nineteen CRVO and seventeen BRVO). All patients had received IVR injection after newly diagnosed. The SFCT was measured at the onset and after two weeks of IVR injection. Paired t test was performed to compare the SFCT of RVO eyes and fellow eyes, as well as the SFCT of pre-injection and post-injection. In further, independent t test was used to compare SFCT and SFCT change between CRVO eyes and BRVO eyes. Results: The mean SFCT at the onset was 326.03±30.86 μm in CRVO eyes, which was significantly thicker than that in contralateral fellow eyes (p<0.01, paired t test), and reduced to 294.15±30.83 μm rapidly after two weeks of IVR injection (p<0.01, paired t test). Similarly, the SFCT in BRVO eyes was significantly thicker than that in contralateral eyes at the onset, and decreased significantly after IVR injection. However, our findings showed that there was no statistically significant difference in SFCT and SFCT reduction after IVR injection between CRVO eyes and BRVO eyes. Conclusions: The SFCT in eyes with ME secondary to CRVO and BRVO was significantly thicker than that in fellow eyes, and decreased significantly within a short time in response to a single IVR injection. In further, the study showed that SFCT and SFCT change had no correlation with RVO subtypes.

show abstract

“…The mean SFCT was reported to be significantly increased in eyes with BRVO compared with the fellow eye, and healthy eyes without BRVO (19,20). The mean SFCT decreased significantly after injections of IVTA, RAN, and DEX (19,21).…”

Section: Discussionmentioning

confidence: 99%

Long-term results of ranibizumab, dexamethasone implant, and triamcinolone in macular edema due to branch retinal vein occlusion

Gökçinar¹

2019

Beyoglu Eye J

View full text Add to dashboard Cite

The present study aims to compare the long-term efficacy and safety results of intravitreal ranibizumab (RAN), dexamethasone intravitreal implant (DEX) and intravitreal triamcinolone acetonide (IVTA) injections in macular edema due to branch retinal vein occlusion (BRVO). Methods: In this retrospective study, one eye each of 43 patients who were treated with intravitreal injections for macular edema secondary to BRVO was recruited into one of the study groups: RAN group (n=17), DEX group (n=16) and IVTA group (n=10). All patients were followed-up for 12 months. Best-corrected visual acuity (BCVA), central macular thickness (CMT), subfoveal choroidal thickness (SFCT) and intraocular pressure (IOP) at month 1, 3, 6, and 12 were compared with baseline. Results: The BCVA increased significantly in the RAN and DEX groups at all visits (all p<0.05). BCVA increase in the IVTA group was significant only at month 1 and 6. CMT decreased significantly in all groups at the end of one year of follow-up (p=0.007; p=0.001; p=0.044, respectively). SFCT significantly decreased in all groups at month 1 (all p<0.05). IOP significantly increased in none, 18.8%, 30% of the patients in the RAN, DEX and IVTA groups, respectively. Cataract surgery was performed in none of the patients, 6.3%, and 30% of the patients in the RAN, DEX, and IVTA groups, respectively. Conclusion: BCVA increase was more prominent in both of the RAN and DEX groups than in the IVTA group. DEX may decrease the injection burden; however, ranibizumab may be a safer choice.

show abstract

Short-term effects of intravitreal dexamethasone implant (OZURDEX®) on choroidal thickness in patients with naive branch retinal vein occlusion

Cited by 8 publications

References 22 publications

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Comparison of subfoveal choroidal thickness in eyes with CRVO and BRVO

Long-term results of ranibizumab, dexamethasone implant, and triamcinolone in macular edema due to branch retinal vein occlusion

Contact Info

Product

Resources

About